Zobrazeno 1 - 10
of 129
pro vyhledávání: '"Sandra Philipp"'
Publikováno v:
Acta Dermato-Venereologica, Vol 100, Iss 14, p adv00214 (2020)
Psoriatic nail symptoms are frequent in psoriasis, affecting up to 80% of patients. Therapy responses to nail symptoms are often limited. In this multicentre non-interventional prospective study, 267 patients with nail involvement were treated with a
Externí odkaz:
https://doaj.org/article/ad6dc8aad9ac4242b9ffa2286c2d559f
Autor:
Robert Sabat, Akewit Chanwangpong, Sylke Schneider-Burrus, Deborah Metternich, Georgios Kokolakis, Agata Kurek, Sandra Philipp, Daniela Uribe, Kerstin Wolk, Wolfram Sterry
Publikováno v:
PLoS ONE, Vol 7, Iss 2, p e31810 (2012)
BACKGROUND: Acne inversa (AI; also designated as Hidradenitis suppurativa) is a common chronic inflammatory skin disease, localized in the axillary, inguinal and perianal skin areas that causes painful, fistulating sinuses with malodorous purulence a
Externí odkaz:
https://doaj.org/article/cc454cb2bee04bf5b2111fdce63b7b87
Autor:
Stefan Haskamp, Steffen Uebe, Rotraut Mößner, Joseph Simon Horowitz, Beate Böhm, Sascha Gerdes, André Reis, Frank Behrens, Knut Schäkel, Gunter Assmann, Vinzenz Oji, Dagmar Wilsmann-Theis, Jörg C. Prinz, Sarah Schuhmann, Sandra Philipp, Kirsten Morrison, Harald Burkhardt, Ulrike Hüffmeier, Volker Schuster, Ansgar Weyergraf, Michael Sticherling, David Simon, Jürgen Rech, Ali Nimeh, Georg Schett, Arnd Jacobi, M. Köhm
Publikováno v:
Journal of Investigative Dermatology. 141:2079-2083
Autor:
Sandra Philipp
Publikováno v:
Kompass Dermatologie. 10:70-72
Background: Children aged ≥ 6 to < 12 years with severe atopic dermatitis (AD) have limited treatment options. In a 16-week, randomized, placebo-controlled, phase III trial in children, dupilumab, a monoclonal antibody inhibiting interleukin (IL)-4
Autor:
Sandra Philipp
Publikováno v:
Kompass Dermatologie. 11:78-79
Risankizumab, a humanized immunoglobin G1 monoclonal antibody that specifically inhibits interleukin 23 by binding to its p19 subunit, is approved in Japan to treat numerous indications, including generalized pustular psoriasis (GPP) and erythrodermi
Autor:
Hendrik Beckert, Sandra Philipp, Julia Pickert, Karl-Christian Bergmann, Ludger Klimek, Regina Treudler, Margita Worm, Torsten Zuberbier, Askin Gülsen, Michèle M Rauber-Ellinghaus, Christian Taube, Uta Jappe, Harald Renz, Thomas Werfel, Martin Wagenmann
Publikováno v:
Allergologie Select
With the advent of biologicals, more and more therapeutics are available that specifically address specific switch points in the pathomechanism of immunologically dominated diseases. Thus, the focus of diagnostics and therapy (precision medicine) is
Autor:
Christian Kromer, Sascha Gerdes, Sandra Philipp, Rotraut Mössner, Andreas Pinter, S. Krebs, Dagmar Wilsmann-Theis
Publikováno v:
Journal of Dermatological Treatment. 32:878-882
Biologic switching is common in psoriasis patients with non-response to or adverse events under therapy with a biologic. However, evidence on efficacy of switching between newly approved biologics of similar mode of action is scarce. The objective wa
Autor:
Uwe Pleyer, Dietmar Krause, Physio Deutschland, K.‑F. Kreitner, Dwg, Drg, Oberschelp U, Uta Kiltz, Schulte Tl, Degam, Dgim, Jean-François Chenot, Dgmm, R. Mössner, Dog, R. Klett, Dgpmr, Annette Becker, DGRh, M. Dreimann, Jürgen Braun, Dgnc, DGORh, Stallmach A, Dgooc, Ddg, K. G. Hermann, Dvmb, L. Hammel, Swoboda B, Arnd Heiligenhaus, Dgrw, Mau W, A. Lauterbach, Schneider E, M. Rudwaleit, Winking M, Uwe Lange, J. Sieper, Sandra Philipp
Publikováno v:
Zeitschrift für Rheumatologie. 78:3-64
Autor:
Sandra Philipp
Publikováno v:
Kompass Dermatologie. 8:111-113
Background: Nail psoriasis is associated with functional impairment, pain and reduced quality of life. Objectives: To demonstrate the superiority of secukinumab over placebo in clearing nail psoriasis as assessed by the Nail Psoriasis Severity Index
Autor:
Sandra Philipp
Publikováno v:
Kompass Dermatologie. 8:16-18
Background: Switching between biologics is commonly performed for the management of plaque psoriasis. However, no evidence about switching from secukinumab to ustekinumab has been reported. Methods: This retrospective observational multicenter study